In short
Odevixibat, also known as A4250, is an investigational drug being studied in clinical trials for the treatment of several rare liver disorders affecting children. These disorders include Progressive Familial Intrahepatic Cholestasis (PFIC), Alagille Syndrome (ALGS), and Biliary Atresia (BA). Odevixibat works by inhibiting a protein called the ileal bile acid transporter (IBAT), which may help reduce bile acid buildup and relieve symptoms like severe itching. This article summarizes key information from recent clinical trials evaluating odevixibat's safety and effectiveness in pediatric patients with these challenging liver conditions.
At a glance
- Drug Name
- Odevixibat (also known as A4250)
- Mechanism of Action
- Selective inhibitor of the ileal bile acid transporter (IBAT)
- Conditions Studied
- Progressive Familial Intrahepatic Cholestasis (PFIC), Alagille Syndrome (ALGS), Biliary Atresia (BA)
- Administration
- Oral capsules, once daily
- Dosage Range
- 40-120 μg/kg/day in most trials
- Primary Outcomes
- Reduction in pruritus (itching), decrease in serum bile acids, improved liver function
- Secondary Outcomes
- Growth parameters, quality of life, delay/prevention of liver transplant
- Trial Durations
- 24-104 weeks, with some having optional extension periods
- Safety Monitoring
- Adverse events, physical exams, laboratory tests, growth measurements
What is Odevixibat?
Odevixibat, also known by its research name A4250, is a new medication designed to treat rare liver diseases in children. It was authorized by the United States Food and Drug Administration on June 13, 2023, for treating cholestatic pruritus (severe itching caused by liver problems) in infants with Alagille Syndrome who are over 12 months old.
How Does Odevixibat Work?
Odevixibat is a small molecule and selective inhibitor of IBAT (Ileal Bile Acid Transporter). This means it works by blocking a specific protein in the intestines that normally helps to recycle bile acids. By doing this, Odevixibat helps to reduce the amount of bile acids in the body, which can help alleviate symptoms associated with certain liver diseases.
What Conditions Does Odevixibat Treat?
Odevixibat is being studied for several rare liver conditions in children, including:
- Alagille Syndrome (ALGS): A genetic disorder that can affect multiple organ systems, including the liver, heart, skeleton, eyes, and kidneys. It often causes blockage of bile flow from the liver, yellowing of the skin (jaundice), poor growth, and severe itching.
- Progressive Familial Intrahepatic Cholestasis (PFIC): A group of rare genetic disorders that affect the liver and can lead to liver failure.
- Biliary Atresia: A condition in infants where the bile ducts outside and inside the liver are scarred and blocked.
Clinical Trials and Research
Odevixibat is currently being studied in several clinical trials:
- ASSERT study: A Phase 3 trial for patients with Alagille Syndrome.
- BOLD study: A Phase 3 trial for children with Biliary Atresia who have undergone a Kasai procedure (a type of surgery for this condition).
- PEDFIC 1 and PEDFIC 2 studies: Phase 3 trials for children with PFIC types 1 and 2.
How is Odevixibat Administered?
Odevixibat is given as capsules for oral administration, usually once daily. The dose is typically based on the child's weight. In most studies, doses of 40 μg/kg/day or 120 μg/kg/day are being tested.
Effectiveness of Odevixibat
The effectiveness of Odevixibat is being measured in several ways:
- Reduction in itching (pruritus): This is often measured using special tools like the Albireo Observer-Reported Outcome (ObsRO) instrument, where caregivers report on the child's scratching behavior.
- Reduction in serum bile acids: This measures the amount of bile acids in the blood.
- Improved growth: Some studies are looking at whether Odevixibat can help improve children's growth.
- Liver health: Researchers are examining various markers of liver health and function.
- Quality of life: Some studies are assessing whether Odevixibat improves overall quality of life for patients.
Safety and Side Effects
The safety of Odevixibat is being closely monitored in all clinical trials. Researchers are tracking any adverse events (side effects) that occur during treatment. So far, the specific side effects have not been detailed in the provided information, but this is a crucial aspect of the ongoing research.
Future Prospects
Odevixibat shows promise in treating several rare liver diseases in children. If the ongoing clinical trials continue to show positive results, it could become an important treatment option for conditions that currently have limited therapeutic choices. Some studies are also looking at the long-term effects of Odevixibat, which will provide valuable information about its use over extended periods.